- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07475949
고급 영상 검사 없이 재관류 치료를 시행한 발병 시각 불명 뇌졸중 (UTOPIA)
비조영 CT 선택 하에 발병 시간을 알 수 없는 급성 허혈성 뇌졸중에 대한 정맥 내 테넥텔플라제 투여: 다기관, 전향적, 무작위, 개방형, 맹검 종말점 임상시험
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.
연구 개요
상태
정황
상세 설명
UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.
Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Dong Pan, MD, PhD
- 전화번호: 86-156 2648 3251
- 이메일: dongpan012@hotmail.com
연구 장소
-
-
Fujian
-
Xiamen, Fujian, 중국, 361004
- 아직 모집하지 않음
- Zhongshan Hospital of Xiamen University
-
연락하다:
- Xingyu Chen
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510620
- 아직 모집하지 않음
- Guangzhou Twelfth People's Hospital
-
연락하다:
- Jianwu Dai
-
-
Guangxi
-
Baise City, Guangxi, 중국, 533000
- 아직 모집하지 않음
- Baise People's Hospital
-
연락하다:
- Dengxing Li
-
Chongzuo, Guangxi, 중국, 532200
- 모병
- The People's Hospital of Chongzuo
-
연락하다:
- Jianyi Huang
-
Guigang, Guangxi, 중국, 537121
- 아직 모집하지 않음
- People's Hospital of Qintang District, Guigang City
-
연락하다:
- Jixin Lu
-
Guigang, Guangxi, 중국, 537200
- 아직 모집하지 않음
- Guiping People's Hospital
-
연락하다:
- Peiquan Yang
-
Laibin, Guangxi, 중국, 545900
- 아직 모집하지 않음
- Wuxuan County People's Hospital
-
연락하다:
- Yu Huang
-
Liuzhou, Guangxi, 중국, 545007
- 아직 모집하지 않음
- Liuzhou Workers' Hospital
-
연락하다:
- Liya Pan
-
Nanning, Guangxi, 중국, 530021
- 아직 모집하지 않음
- The First Affiliated Hospital of Guangxi Medical University
-
연락하다:
- Dong Pan, MD, PhD
- 전화번호: 86-156 2648 3251
- 이메일: dongpan012@hotmail.com
-
수석 연구원:
- Yuan Wu, MD, PhD
-
Nanning, Guangxi, 중국, 530200
- 아직 모집하지 않음
- Nanning Yongning District People's Hospital
-
연락하다:
- Wuqiao Liang
-
연락하다:
- Qihai Zhou
-
Nanning, Guangxi, 중국, 530219
- 아직 모집하지 않음
- Guangxi Medical University Kaiyuan Langdong Hospital
-
연락하다:
- Kai Chen
-
Nanning, Guangxi, 중국, 530409
- 아직 모집하지 않음
- No.9 People's Hospital of Nanning
-
연락하다:
- Jun Qu
-
Qinzhou, Guangxi, 중국, 535000
- 아직 모집하지 않음
- The Second People's Hospital of Qinzhou
-
연락하다:
- Caixia Xuan
-
-
Shaanxi
-
Yulin, Shaanxi, 중국, 718100
- 아직 모집하지 않음
- Mizhi County Hospital
-
연락하다:
- Tao Zhang
-
Yulin, Shaanxi, 중국, 718600
- 아직 모집하지 않음
- Dingbian County People's Hospital
-
연락하다:
- Gaiyan Qu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 18 years old.
- Clinical diagnosis of acute ischemic stroke.
- Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
- Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
- National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
- Planned endovascular treatment.
- Rapid neurological improvement with NIHSS <6 at randomization.
- Allergy to tenecteplase.
- Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
- Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
- Severe traumatic brain injury or other major trauma in the past 3 months.
- Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
- Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
- Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
- Active internal bleeding.
- Aortic dissection.
- Infective endocarditis.
- Platelet count <100×10^9/L.
- Women who are pregnant or breastfeeding.
- Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
- Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
- Life expectancy <3 months.
- Participating in other trials.
- Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Control group
Standard Medical Treatment |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. |
|
실험적: Tenecteplase group
Intravenous tenecteplase thrombolysis |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Excellent outcome
기간: 90 (±14) days
|
The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days |
90 (±14) days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Level of disability
기간: 90 (±14) days
|
Ordinal shift analysis of the mRS with 5-6 merged at 90 days. |
90 (±14) days
|
|
Functional independence
기간: 90 (±14) days
|
The proportion of mRS score of 0-2 at 90 days. |
90 (±14) days
|
|
Early neurological improvement
기간: 24 (±12) hours
|
The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours. |
24 (±12) hours
|
|
Change in stroke severity
기간: 7 (±1) days or at discharge
|
The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first) |
7 (±1) days or at discharge
|
|
Quality of life measured by EQ-5D-5L
기간: 90 (±14) days
|
EQ-5D-5L scale score at 90 days. |
90 (±14) days
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Symptomatic intracranial hemorrhage
기간: 24 (±12) hours
|
Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria) |
24 (±12) hours
|
|
Any intracranial hemorrhage
기간: 24 (±12) hours
|
Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification) |
24 (±12) hours
|
|
Extracranial bleeding
기간: 24 (±12) hours
|
Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization |
24 (±12) hours
|
|
Mortality
기간: 90 days
|
All cause death within 90 days. |
90 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2026-K0237
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .